Healing & Recovery Protocol
KPV (Alpha-MSH Fragment)Complete dosing & administration guide
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Dose Range
300-500mcg
Frequency
Once daily
Route
Oral
Cycle Length
Ongoing/indefinite
Dosing
How much
do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Starting Dose
200 mcg
Lower end of the subcutaneous practice range for systemic anti-inflammatory use; KPV is the C-terminal tripeptide of alpha-MSH and acts on NF-kB signaling [3][6].
Standard Dose
300-500 mcg
Most commonly used subcutaneous practice dose for systemic/extra-intestinal inflammation; some practitioners escalate toward 500 mcg during acute flares [6].
Timing
Best time to take
Take KPV (Alpha-MSH Fragment) at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
KPV (Alpha-MSH Fragment) can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
KPV (Alpha-MSH Fragment) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
Administration
How do I
use it?
Reconstitution
What you need
- •KPV (Alpha-MSH Fragment) in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
KPV (Alpha-MSH Fragment) is administered Oral—no injection required
Best sites
- •Not applicable—this is not an injectable formulation
Technique
- 1.Follow the specific administration instructions for your KPV (Alpha-MSH Fragment) formulation
- 2.Take or apply as directed by your healthcare provider
- 3.Store properly between uses according to package instructions
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
KPV safety data come from in vitro mechanistic studies, rodent models, and limited human topical application research. Published research in Journal of Neuroimmunology demonstrates selective anti-inflammatory activity without systemic toxicity signals in animal models. Human safety data are restricted primarily to pilot studies and unpublished investigations, placing KPV in the research compound category with incomplete clinical characterization. Animal studies show no organ toxicity or genotoxicity at relevant doses.
Common Side Effects
Experienced by some users
Injection Site Reaction
Potential mild redness, swelling, or discomfort at subcutaneous injection site as expected with peptide administration
Management: Rotate injection sites; apply ice if needed; standard subcutaneous injection technique
Mild GI Effects
Theoretical mild gastrointestinal symptoms with oral administration as peptide interacts with intestinal epithelium
Management: Take with food if GI discomfort occurs; start with lower doses and titrate upward
Transient Skin Effects
With topical application, potential mild irritation or redness at application site during initial use
Management: Patch test before widespread application; reduce concentration if irritation occurs
Mild Immune Modulation
Anti-inflammatory effects may transiently alter local immune responses at sites of inflammation
Management: Monitor for signs of infection; effects are expected to be reversible upon discontinuation
Peptide Stability Concerns
As a small peptide, KPV is susceptible to proteolytic degradation which may affect bioavailability rather than cause side effects
Management: Use nanoparticle or hydrogel formulations for improved stability; subcutaneous route may offer better bioavailability than oral
Less Common
- •Theoretical Immunosuppression
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with KPV (Alpha-MSH Fragment)
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
KPV (Alpha-MSH Fragment) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓BPC-157 - Complementary gut-healing peptide that promotes mucosal repair while KPV addresses underlying inflammation
- ✓Thymosin Alpha-1 - Immune-modulating peptide that can complement KPV anti-inflammatory effects for balanced immune regulation
- ✓L-Glutamine - Amino acid that supports intestinal barrier function and mucosal integrity alongside KPV anti-inflammatory action
With medications
- !High-Dose Immunosuppressants - Additive immune suppression may increase infection risk through overlapping anti-inflammatory mechanisms
- !Melanotan Peptides - Potential overlapping melanocortin receptor activation could produce unpredictable combined effects
- !Systemic Corticosteroids - Redundant anti-inflammatory pathways may confound therapeutic outcomes or cause excessive immune suppression
With supplements
- ✓Multivitamins - Generally safe to take alongside KPV (Alpha-MSH Fragment). Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Published Research
What the studies show
Sun J, et al. · 2021
A novel hydrogel delivery system stabilized KPV for ulcerative colitis treatment, showing 50% reduction in colonic myeloperoxidase activity in rat models. Intestinal epithelial barrier function was preserved, preventing disease progression.
Xiao B, et al. · 2017
Hyaluronic acid-nanoparticles delivered KPV directly to inflamed intestinal epithelium, achieving stronger anti-inflammatory effects than standard delivery. TNF-α was significantly downregulated, demonstrating targeted efficacy.
Brzoska T, et al. · 2008
This comprehensive review established KPV as a potent anti-inflammatory tripeptide derived from alpha-MSH that lacks the pigmentary effects of the parent hormone. KPV shows promise for treating inflammatory bowel disease, fibrosis, and arthritis.
Kannengiesser K, et al. · 2008
Original preclinical research demonstrated KPV efficacy in multiple murine inflammatory bowel disease models with approximately 50% reduction in colonic myeloperoxidase activity. The mechanism involved NF-κB pathway inhibition.
Brzoska T, et al. · 2010
Analysis revealed KPV's anti-inflammatory effects work through NF-κB and MAP kinase pathway inhibition—the same mechanism as full-length alpha-MSH but without unwanted side effects. KPV represents a minimal anti-inflammatory fragment.
PeptidesExplorer (practitioner protocol compilation) · 2026
Documents commonly used research/practice KPV doses: 200-500 mcg subcutaneous daily, 1000-1500 mcg oral daily for gut inflammation, and 0.01-0.1% topical formulations twice daily; notes no completed human trial has established an official dose.
Head to Head
KPV (Alpha-MSH Fragment) compared
Want the Full Picture?
View the complete KPV (Alpha-MSH Fragment) research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.